ReviewStem cell research & therapy2024
Exosomes as promising bioactive materials in the treatment of spinal cord injury.
Review in Stem cell research & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Exosomes target liver TREM-1 to break the systemic inflammatory cascade and improve spinal cord injury outcomes.Journal of orthopaedic translation · 2026Article
- Recent Advances in Diversified Materials for Spinal Cord Injury Repair and Regeneration.Gels (Basel, Switzerland) · 2026Review
- Plasticity, injury-induced reprogramming, and translational applications of Schwann cells in neural regeneration.Frontiers in cellular neuroscience · 2026Review
- Synergistic effects of tanshinone IIA and mesenchymal stem cells on neuroprotection, cardiovascular repair, tissue regeneration, muscle protein synthesis, and gut microbiota modulation across neurodegenerative, cardiovascular, and regenerative disease models.Frontiers in cell and developmental biology · 2026Review
- Exosome Cargo Molecules and NLRP3/BDNF: Clinical and Preclinical Evidence for Acupuncture-Mediated Spinal Cord Injury Recovery.International journal of general medicine · 2026Review
- Exosome-derived ncRNAs and proteins: inflammation regulatory mechanisms and biomarker potential in spinal cord injury.Frontiers in molecular biosciences · 2026Review
- Clinical Efficacy of Stem Cell Therapy in Neurotraumatic and Neurodegenerative Conditions: A Comparative Review.Tissue engineering and regenerative medicine · 2025Review
- Roles for Exosomes from Various Cellular Sources in Spinal Cord Injury.Molecular neurobiology · 2025Review
- Extracellular vesicles derived from Schwann cells to enhance bone and dental tissue regeneration: a literature review.Journal of nanobiotechnology · 2025Review
- Injectable extracellular vesicle hydrogels with tunable viscoelasticity for depot vaccine.Nature communications · 2025Article
- Harnessing stem cell-derived exosomes: a promising cell-free approach for spinal cord injury.Stem cell research & therapy · 2025Review
- Stem Cell-Derived Extracellular Vesicle-Mediated Therapeutic Signaling in Spinal Cord Injury.International journal of molecular sciences · 2025Review
- The potential mechanisms and regulatory roles of exosomal miRNA in neural repair after spinal cord injury.Frontiers in cellular neuroscience · 2025Review
- How Advanced Are Exosomes as Cell-Free Therapeutics for Spinal Cord Injury?International journal of nanomedicine · 2025Review
- Exosomes: a promising microenvironment modulator for spinal cord injury treatment.International journal of biological sciences · 2025Review
- Antioxidant nanozymes: current status and future perspectives in spinal cord injury treatments.Theranostics · 2025Review
- Bibliometric Analysis of Exosome Research in Spinal Cord Injury (2000-May 2024). Trends, Collaborations, and Emerging Insights.Drug design, development and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Patients with spinal cord injury (SCI) have permanent devastating motor and sensory disabilities. Secondary SCI is known for its complex progression and presents with sophisticated aberrant inflammation, vascular changes, and secondary cellular dysfunction, which aggravate the primary damage. Since their initial discovery, the potent neuroprotective effects and powerful delivery abilities of exosomes (Exos) have been reported in different research fields, including SCI. In this study, we summarize therapeutic advances related to the application of Exos in preclinical animal studies. Subsequently, we discuss the mechanisms of action of Exos derived from diverse cell types, including neurogenesis, angiogenesis, blood-spinal cord barrier preservation, anti-apoptosis, and anti-inflammatory potential. We also evaluate the relationship between the Exo delivery cargo and signaling pathways. Finally, we discuss the challenges and advantages of using Exos to offer innovative insights regarding the development of efficient clinical strategies for SCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.